CN105445469B - A kind of detection kit of ischemia modified albumin IMA - Google Patents
A kind of detection kit of ischemia modified albumin IMA Download PDFInfo
- Publication number
- CN105445469B CN105445469B CN201410436469.XA CN201410436469A CN105445469B CN 105445469 B CN105445469 B CN 105445469B CN 201410436469 A CN201410436469 A CN 201410436469A CN 105445469 B CN105445469 B CN 105445469B
- Authority
- CN
- China
- Prior art keywords
- albumin
- content
- reagent
- detection kit
- ischemia modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a kind of detection kit of ischemia modified albumin IMA.Specifically, kit of the invention includes cobalt ions and dithiothreitol (DTT).On the one hand the kit of the present invention by adding stabilizer, adds the storage stability of kit, on the other hand by adding solubilizer, removes the pollution of reagent contrastive colours device.
Description
Technical field
The present invention relates to clinical examination field, and in particular, to a kind of improved ischemia modified albumin IMA detection kit.
Background technology
Ischemia modified albumin IMA (Ischemia-modified albumin, IMA) refers in tissue ischemia and Reperfu- sion hair
When raw, N-terminal amino acid is modified the albumin of (binding site is occupied or is acetylation or lack by copper ion), its main feature is that
Decline with the binding ability of transition metal (nickel, copper, cobalt).
IMA is i.e. rapid in 5-10 minutes after myocardial ischemia to be raised, and is returned to baseline in 6-12h, is after myocardial ischemia occurs
An early stage index before meronecrosis.Compared with the index of other reflecting myocardiums infraction such as CK-MB, Myo, cTn, its power
Learn curve to show, the time zone that it is produced is more forward, judges myocardial ischemia sensitivity higher.
Clinically, IMA is mainly used in the early diagnosis of acute myocardial ischemia, and acute coronary syndrome
(ACS) early diagnosis and risk stratification.Sinha researchs show opposite electrocardiogram (ECG) and troponin T, and IMA is lacked as cardiac muscle
Blood index sensitivity highest.Diagnosis ACS is combined with ECG or troponin T, detection sensitivity can be significantly improved.At the same time
Some researches show that IMA is not only to judge the good index of myocardial ischemia, and its elevated level is also serious with myocardial ischemia
Degree is related.Also it is reported that, IMA's specific relatively low, acute infection, end-stage renal disease, prostatic disorders and hepatic sclerosis
IMA can be caused to raise etc. disease.
At present, IMA as evaluation myocardial ischemia index, be approved by the FDA in the United States by, while be also unique one
Judge the index of myocardial ischemia.Therefore, which has broad application prospects.
At present IMA predominantly detect method be albumin cobalt Binding experiment (albumin-cobalt binding assay,
ACB).Its main measuring principle is：
The first step：
Excessive Co2++ albumin → Co- albumin+residue Co2+
Excessive Co2++ IMA → do not combine；
Second step：
Remaining Co2++ color developing agent → color products.
Ischemia modified albumin IMA is to Co2+Binding ability is less than normal albumin, Human Serum Albumin and excess Co2+With reference to
Afterwards, remaining free Co2+It is coloured with organic chromogenic thing (dithiothreitol (DTT) and the like or azo color developing agent etc.) reaction generation
(red or blueness) product, carries out colorimetric, its absorbance and Co under certain wavelength2+Concentration, IMA contents are directly proportional, with mark
Quasi- product are compared, you can calculate the concentration of IMA in sample.
In ACB experiments, after cobalt ions is combined with color developing agent, the compound water solubility of formation is very poor.Particularly work as sample
In the IMA higher concentrations that contain or during detection blank sample, it is high to react the complex concentration of generation, can directly react
Separate out and adsorbed in the colorimetric device of instrument in journey.This pollutes instrument, and then influences the analytical performance of whole instrument.
In addition also have using assay methods such as ELISA, HPLC/MS, but due to inconvenient for operation, using seldom.
The content of the invention
According to certain embodiments of the present invention, there is provided a kind of side for improving the pollution of albumin cobalt Binding experiment Instrumental
Method, it includes step：1) sample to be tested is provided, 2) sample to be tested is contacted with the first reagent, 3) make sample to be tested and the afterwards
Two reagents contact.It should be appreciated that any albumin cobalt Binding experiment as known in the art (ACB experiments) is suitable for the present invention
Improve the method for pollution, such as, but not limited to《Cardiovascular Biomarkers:Pathophysiology and
Disease Management》Springer publishing houses 2010；《Biomarkers in Heart Disease》James de
Lemos.John Wiley＆Sons, those described in 2009.
In some specific embodiments, the first reagent includes：Buffer solution and Co2+；Second reagent includes：Buffer solution
And color developing agent.Compared with albumin cobalt Binding experiment of the prior art, one of method difference of the invention is to react
Solubilizer is further included in system.In some specific embodiments, in the first reagent, and/or in the second reagent, even
And/or contain solubilizer in the 3rd reagent or in each reagent；Solubilizer one or more chosen from the followings：In vain
Albumen, methanol, ethanol, propane diols, glycerine, isopropanol, isoamyl alcohol and dimethyl sulfoxide (DMSO).In a preferred embodiment
In, solubilizer is albumin (such as BSA) or glycerine.In some specific embodiments, when solubilizer is albumin,
The content of albumin is 0.01-20%, be, for example, 0.01,0.02,0.03,0.04,0.05,0.06,0.07,0.08,0.09,
0.1、0.15、0.2、0.25、0.3、0.35、0.4、0.45、0.5、0.55、0.6、0.65、0.7、0.75、0.8、0.85、0.9、
0.95、1.0、1.5、1.6、1.7、1.8、1.9、2.0、2.5、3.0、3.5、4、4.5、5、5.5、6、6.5、7、8、9、10、15、
16th, the scope between 18,20% or above-mentioned any two end value, preferably 0.05-2%, more preferably 0.1-1%, most preferably
0.2%；In some preferred embodiments, content of the albumin in the 1st reagent is 0.2%.When solubilizer is albumin
During solubilizer in addition, its content is 0.1-20%, for example, 0.1,0.15,0.2,0.25,0.3,0.35,0.4,0.45,0.5,
0.55、0.6、0.65、0.7、0.75、0.8、0.85、0.9、0.95、1.0、1.5、1.6、1.7、1.8、1.9、2.0、2.5、3.0、
3.5th, the scope between 4,4.5,5,5.5,6,6.5,7,8,9,10,15,16,18,20% or above-mentioned any two end value, it is excellent
Select 0.2-10%, more preferably 0.5-5%；In one preferred embodiment, content of the glycerine in the 2nd reagent is 2%.
It is although without being bound by any theory, it will be understood that, for method of the invention by introducing solubilizer, increase is compound
The dissolubility of thing in a solvent, and then remove pollution of the reaction product to instrument colorimetric device.
The present processes are used equally for suitable for any sample to be tested of albumin cobalt Binding experiment in the prior art, are selected
From whole blood, serum, blood plasma and urine.
In some specific embodiments, the reagent (such as second reagent) where stabilizer also includes stabilizer.Surely
Determine agent and be preferably three (2- carboxyethyls) phosphines-hydrochloride.The content of stabilizer is 0.05-100 mM, for example, 0.05,0.1,0.2,
0.3rd, 0.5,1.0,2.0,3.0,5.0,6.0,8.0,10,12,15,20,25,30,40,50,60,70,80,90,100mM or
Scope between above-mentioned any two end value, most preferably preferably 0.2-20mM, 1mM.Although without being bound by any theory, can with this
Sample understands, since color developing agent (such as dithiothreitol (DTT)) is reducing substances, is holding as liquid reagent box in use, placing for a long time
Easily by the dioxygen oxidation in air, and then cause to lose coloration ability.Therefore, method of the invention can be by adding stability group
Point, increase stability of the color developing agent in fluid matrix, increase the storage stability of reagent.
In some specific embodiments, buffer solution is selected from following one or more：Good's buffer solutions, phosphoric acid buffer
Liquid, glycine buffer and acetate buffer, buffer concentration 10-500mM, 10-50mM, 50-100mM, 100-200mM,
200-300mM、300-500mM。
In some specific embodiments, Co2+It is selected from：Cobalt chloride, cobaltous sulfate, cobalt nitrate, cobalt borate；The Co2+'s
Content is 0.01-10mM, preferably 0.05-2mM, more preferably 0.1-0.5mM, most preferably 0.3mM.
In some specific embodiments, color developing agent is dithiothreitol (DTT), and the content of the color developing agent is 0.1-
100mM, preferably 1-10mM, more preferably 2-5mM, most preferably 3mM.
Other are embodiment there is provided a kind of ischemia modified albumin IMA detection kit according to the present invention, it includes：
Wherein solubilizer one or more chosen from the followings：Albumin, methanol, ethanol, propane diols, glycerine, isopropanol,
Isoamyl alcohol and dimethyl sulfoxide (DMSO).
In some specific embodiments, kit also includes stabilizer.Stabilizer be preferably three (2- carboxyethyls) phosphines-
Hydrochloride.The content of stabilizer is 0.05-100mM, preferably 0.2-20mM, more preferably 0.5-5mM, most preferably 1mM.
Compared with IMA detection kits of the prior art, one of kit difference of the invention is kit
In further include solubilizer.In some specific embodiments, in the first reagent, and/or in the second reagent, even and/
Or contain solubilizer in the 3rd reagent or in each reagent.Solubilizer one or more chosen from the followings：White egg
In vain, methanol, ethanol, propane diols, glycerine, isopropanol, isoamyl alcohol and dimethyl sulfoxide (DMSO).In one preferred embodiment,
Solubilizer is albumin or glycerine.In some specific embodiments, when solubilizer is albumin, the content of albumin
For 0.01-20%, preferably 0.05-2%, more preferably 0.1-1%, most preferably 0.2%；In one preferred embodiment, in vain
Content of the albumen in the 1st reagent is 0.2%.When the solubilizer beyond solubilizer is albumin, its content is 0.1-20%,
It is preferred that 0.2-10%, more preferably 0.5-5%, most preferably 2%；In one preferred embodiment, glycerine is in the 2nd reagent
Content be 2%.
In some embodiments, the buffer solution in kit is selected from following one or more：Good's buffer solutions, phosphoric acid
Buffer solution, glycine buffer and acetate buffer.Buffer solution in first reagent and the second reagent can it is identical can not also
Together, it is preferably identical.In some embodiments, Co2+Selected from cobalt chloride, cobaltous sulfate, cobalt nitrate, cobalt borate；The Co2+Contain
Measure as 0.05-2mM, more preferably 0.1-0.5mM, most preferably 0.3mM.In some embodiments, color developing agent is dithiothreitol (DTT),
The content of the color developing agent is 1-10mM, more preferably 2-5mM, most preferably 3mM.
Technical staff is appreciated that the kit can be prepared into any appropriate form, three reagents or double reagent
Form, is generally prepared as the form of double reagent.Kit can be powdered reagent, i.e., be dissolved in water before use；Can also be liquid
Body reagent, directly uses.Technical staff is further appreciated that in order to avoid developing the color in advance, Co2+From color developing agent positioned at different
In reagent.Such as in some embodiments, Co2+In the first reagent, and color developing agent is located in the second reagent.In some realities
Apply in mode, color developing agent and stabilizer are located in same reagent.
In some embodiments, kit can also include the auxiliary elements such as surfactant, and/or preservative, dense
Respectively between 0.01 to 2%, this can voluntarily be determined degree by technical staff.
According to a specific embodiment, ischemia modified albumin IMA detection kit of the invention, comprising or by as follows
Composition：
Reagent 1：
Good ' s buffer solution 50mM,
Cobalt chloride 0.3mM,
Triton X-405 0.1%；
Reagent 2：
According to another specific embodiment, ischemia modified albumin IMA detection kit of the invention, comprising or by such as
Lower composition：
Reagent 1：
2 component of reagent and concentration：
Good ' s buffer solution 100mM,
Dithiothreitol (DTT) 5mM,
Three (2- carboxyethyls) phosphine-hydrochloride 5mM.
According to the present invention other embodiment there is provided a kind of preparation side of ischemia modified albumin IMA detection kit
Method, the kit of the present invention is prepared according to conventional method well known in the art, it is characterised in that including adding solubilising into reagent
The step of agent.Solubilizer one or more chosen from the followings：It is albumin, methanol, ethanol, propane diols, glycerine, isopropanol, different
Amylalcohol and dimethyl sulfoxide (DMSO).In one preferred embodiment, solubilizer is albumin or glycerine.It is specific real at some
Apply in mode, when solubilizer is albumin, the content of albumin is 0.01-20%, preferably 0.05-2%, more preferably 0.1-
1%, most preferably 0.2%；In one preferred embodiment, content of the albumin in the 1st reagent is 0.2%.Work as solubilising
When agent is the solubilizer beyond albumin, its content is 0.1-20%, preferably 0.2-10%, more preferably 0.5-5%, most preferably
2%；In one preferred embodiment, content of the glycerine in the 2nd reagent is 2%.
Remaining cobalt ions can use method well known in the art caused by detection IMA, can pass through electrochemistry, change
The methods of give out light, can also use the instrument detection reaction including ion analyser.
The kit of detection ischemia modified albumin IMA provided by the invention, can be in automatic clinical chemistry analyzer and semi-automatic
Used on Biochemical Analyzer, it is not necessary to which other instruments, measurement result is accurate, and speed is fast, reproducible, and stability is good, resists dry
It is strong to disturb ability, easy to promote the use of.
Brief description of the drawings
Fig. 1 shows concentration of specimens range of linearity when kit 2 of the present invention measures sample.
Embodiment
The present invention will be further illustrated by following non-limiting examples below, it is well known to those skilled in the art, not
In the case of spirit of the invention, many modifications can be made to the present invention, such modification also falls into the scope of the present invention.
Unless otherwise instructed, used experiment material can be obtained easily following experimental methods from commercial company.
Embodiment 1：The preparation method of kit of the present invention
According to following component, kit is configured to the form of liquid double reagent.
First composition of 1. kit of the present invention of kit is double reagent kit, its component is as follows：
1 component of reagent and concentration：
Good ' s buffer solutions：50mM, pH 8.0
Cobalt chloride：0.3mM,
Triton X-405:0.1%；
2 component of reagent and concentration：
2nd composition of 2. kit of the present invention of kit is double reagent kit, its component is as follows：
1 component of reagent and concentration：
2 component of reagent and concentration：
Good ' s buffer solutions：100mM,
Dithiothreitol (DTT):5mM,
Three (2- carboxyethyls) phosphines-hydrochloride: 5mM.
The application method of 2. kit of embodiment
This detection method is performance rate method.
1) serum sample is provided,
2) after 150 μ L reagents 1 are mixed with 20 μ L serum samples, 37 DEG C of incubation 5min, detect absorbance A 1 under 505nm,
3) 50 μ L reagents 2 are added, then are incubated 5min, absorbance A 2 under 505nm when detecting 5min.So as to calculate in sample
The concentration of IMA.Other appropriate detection modes well known in the art and operating procedure can also use.
1. study on the stability of test case
This kit 1 is put into 2-8 DEG C 10 months, investigates reagent stability.The change of Main Basiss blank absorbency comes
Investigate.Experimental result is shown in Table 1.As can be seen that this kit has good stability.
Table 1：The stability result of kit 1 of the present invention
Test case 2：Repeatability, the range of linearity and antifouling property
(1) using the horizontal survey at the same time of kit 2 of the present invention with an example serum sample 20 times, detection kit measurement sample
The repeatability of this when, the results are shown in Table 2.
Table 2：Kit 2 of the present invention measures repeated result during serum sample
(2) serum high level and low value sample are used, is detected with the kit 2 of the present invention, verifies kit of the present invention
Measure concentration of specimens range of linearity during sample, the result is shown in Figure 1.As it can be seen that the kits repeatability of the present invention is high, line is measured
Property scope is wide.
(3) kit 1 or 2 is measured to the blank absorbency of R1 on Beckman AU series models respectively, ensures each batch
Secondary detection uses same cuvette, investigates the absorbance change of cuvette before and after detection.
Table 3：Influence of the kit 2 of the present invention to reagent contamination performance (solubilizer is in R1)
Table 4：Influence of the kit of the embodiment of the present invention 1 to reagent contamination performance (solubilizer is in R2)
, it is apparent that the kit of the present invention, after once measure was done, contrastive colours cup does not influence, and right
Than kit, then contrastive colours cup produces obvious absorption pollution, and then influences the analytical performance of whole detecting instrument.
Claims (29)
1. a kind of ischemia modified albumin IMA detection kit, it includes the first reagent and the second reagent,
Wherein, included in first reagent：
Buffer solution 10mM to 500mM,
Co2+0.01mM to 10mM；
Included in second reagent：
Buffer solution 10mM to 500mM,
Color developing agent 0.1mM to 100mM；
Also contain albumin in the first reagent and/or the second reagent, content of the albumin based on mass/volume for 0.05% to
2%.
2. ischemia modified albumin IMA detection kit according to claim 1, is three also comprising stabilizer, the stabilizer
(2- carboxyethyls) phosphine-hydrochloride；
The content of the stabilizer is 0.2mM to 20mM.
3. ischemia modified albumin IMA detection kit according to claim 2, the content of three (2- carboxyethyls) phosphine-hydrochlorides
For 0.5mM to 5mM.
4. ischemia modified albumin IMA detection kit according to claim 2, the content of three (2- carboxyethyls) phosphine-hydrochlorides
For 1mM.
5. ischemia modified albumin IMA detection kit according to claim 1, wherein：
The content of albumin is calculated as 0.1% to 1.0% by mass/volume.
6. ischemia modified albumin IMA detection kit according to claim 5, wherein：
The content of albumin is calculated as 0.2% by mass/volume.
7. ischemia modified albumin IMA detection kit according to claim 1, wherein：
Buffer solution is selected from following one or more：Good's buffer solutions, phosphate buffer, glycine buffer and acetate buffer
Liquid；
Co2+It is selected from：Cobalt chloride, cobaltous sulfate, cobalt nitrate, cobalt borate；
The Co2+Content be 0.05mM to 2mM；
Color developing agent is dithiothreitol (DTT), and the content of the color developing agent is 1mM to 10mM.
8. ischemia modified albumin IMA detection kit according to claim 7, wherein：
The Co2+Content be 0.1mM to 0.5mM.
9. ischemia modified albumin IMA detection kit according to claim 8, wherein：
The Co2+Content be 0.3mM.
10. ischemia modified albumin IMA detection kit according to claim 7, wherein：
The content of the color developing agent is 2mM to 5mM.
11. ischemia modified albumin IMA detection kit according to claim 10, wherein：
The content of the color developing agent is 3mM.
12. ischemia modified albumin IMA detection kit according to claim 1, the kit is three reagents or double reagent
Form；Wherein Co2+It is located at different reagents from color developing agent.
13. ischemia modified albumin IMA detection kit according to claim 1, also comprising surfactant, by quality/body
Product meter concentration is 0.01% to 2%.
14. ischemia modified albumin IMA detection kit according to claim 1, also comprising preservative, based on mass/volume
Concentration is 0.01% to 2%.
15. a kind of ischemia modified albumin IMA detection kit, it includes：
First reagent：
Second reagent：
Good ' s buffer solution 100mM,
Dithiothreitol (DTT) 5mM,
Three (2- carboxyethyls) phosphine-hydrochloride 5mM.
A kind of 16. method of the ischemia modified albumin IMA detection kit prepared described in claim 1, it is characterised in that method bag
Include the step of albumin is added into reagent；
Content of the albumin based on mass/volume is 0.05% to 2%.
17. the method according to claim 11, wherein：
The content of albumin is calculated as 0.1% to 1.0% by mass/volume.
18. the method according to claim 11, wherein：
The content of albumin is calculated as 0.2% by mass/volume.
19. a kind of method for improving the pollution of albumin cobalt Binding experiment Instrumental, it includes step：
1) provide sample to be tested,
Sample to be tested is contacted with the first reagent,
3) sample to be tested is made to be contacted with the second reagent after；
Wherein
First reagent includes buffer solution and Co2+；
Second reagent includes buffer solution and color developing agent；
Also contain solubilizer albumin in wherein the first reagent and/or the second reagent, content of the albumin based on mass/volume is
0.05% to 2%；
Sample to be tested is selected from：Whole blood, serum, blood plasma and urine.
20. the method according to claim 19 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein：
The content of albumin is calculated as 0.1% to 1.0% by mass/volume.
21. the method according to claim 20 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein albumin
Content is calculated as 0.2% by mass/volume.
22. the method according to claim 19 for improving the pollution of albumin cobalt Binding experiment Instrumental, second reagent
Stabilizer is also included,
The stabilizer is three (2- carboxyethyls) phosphines-hydrochloride, its content is 0.2mM to 20mM.
23. the method according to claim 22 for improving the pollution of albumin cobalt Binding experiment Instrumental, three (2- carboxyethyls)
The content of phosphine-hydrochloride is 0.5mM to 5mM.
24. the method according to claim 23 for improving the pollution of albumin cobalt Binding experiment Instrumental, three (2- carboxyethyls)
The content of phosphine-hydrochloride is 1mM.
25. the method according to claim 19 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein：
Buffer solution is selected from following one or more：Good's buffer solutions, phosphate buffer, glycine buffer and acetate buffer
Liquid, buffer concentration are 10mM to 500mM；
Co2+It is selected from：Cobalt chloride, cobaltous sulfate, cobalt nitrate, cobalt borate；
The Co2+Content be 0.05mM to 2mM；
Color developing agent is dithiothreitol (DTT), and the content of the color developing agent is 1mM to 10mM.
26. the method according to claim 25 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein the Co2+'s
Content is 0.1mM to 0.5mM.
27. the method according to claim 26 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein the Co2+'s
Content is 0.3mM.
28. the method according to claim 25 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein the colour developing
The content of agent is 2mM to 5mM.
29. the method according to claim 28 for improving the pollution of albumin cobalt Binding experiment Instrumental, wherein the colour developing
The content of agent is 3mM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410436469.XA CN105445469B (en) | 2014-08-29 | 2014-08-29 | A kind of detection kit of ischemia modified albumin IMA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410436469.XA CN105445469B (en) | 2014-08-29 | 2014-08-29 | A kind of detection kit of ischemia modified albumin IMA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105445469A CN105445469A (en) | 2016-03-30 |
| CN105445469B true CN105445469B (en) | 2018-05-01 |
Family
ID=55555906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410436469.XA Active CN105445469B (en) | 2014-08-29 | 2014-08-29 | A kind of detection kit of ischemia modified albumin IMA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105445469B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108152225B (en) * | 2017-11-29 | 2020-11-06 | 武汉生之源生物科技股份有限公司 | Determination method and detection kit for ischemia modified albumin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101421626A (en) * | 2006-02-15 | 2009-04-29 | 因弗因斯医药瑞士股份有限公司 | Measure |
| CN102607999A (en) * | 2011-01-19 | 2012-07-25 | 索尼公司 | Method and device for detecting heavy metal ion in water |
| WO2014047278A1 (en) * | 2012-09-20 | 2014-03-27 | Viracor-Ibt Laboratories | A method for determination of cellular immune response to therapeutic vaccines |
| CN103760357A (en) * | 2013-11-04 | 2014-04-30 | 山东博科生物产业有限公司 | Detection kit for ischemia modified albumin |
-
2014
- 2014-08-29 CN CN201410436469.XA patent/CN105445469B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101421626A (en) * | 2006-02-15 | 2009-04-29 | 因弗因斯医药瑞士股份有限公司 | Measure |
| CN102607999A (en) * | 2011-01-19 | 2012-07-25 | 索尼公司 | Method and device for detecting heavy metal ion in water |
| WO2014047278A1 (en) * | 2012-09-20 | 2014-03-27 | Viracor-Ibt Laboratories | A method for determination of cellular immune response to therapeutic vaccines |
| CN103760357A (en) * | 2013-11-04 | 2014-04-30 | 山东博科生物产业有限公司 | Detection kit for ischemia modified albumin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105445469A (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106198527B (en) | A kind of ascorbic acid interference multi-term urine analysis test paper and preparation method thereof | |
| CN104198473B (en) | A kind of uric acid detection kit of stabilization | |
| JP5925026B2 (en) | Dry specimen for creatinine measurement and creatinine measurement method | |
| CN104198726B (en) | A kind of stable homocysteine detection kit | |
| CN104198408A (en) | Detection kit for determining content of creatinine in serum by enzymic method | |
| CN105671127B (en) | A kind of stable enzyme process serum Mg-ion detection kit | |
| CN112285367B (en) | Kit for detecting calcium ions and application thereof | |
| CN102864206A (en) | Anti-heparin interference leucine aminopeptidase measuring reagent | |
| CN107656069A (en) | Full-range C reactive protein quantitative detecting reagent and method in whole blood | |
| CN104198407A (en) | Detection kit for detecting content of beta-hydroxybutyrate in serum by adopting stable enzymatic method | |
| CN103048282B (en) | Detection method of bilirubin and detection kit | |
| CN105445469B (en) | A kind of detection kit of ischemia modified albumin IMA | |
| CN109613232A (en) | A kind of detection kit and detection method of complete homogeneous determination adiponectin | |
| CN104048928A (en) | Detection kit for direct bilirubin | |
| CN106443014B (en) | Detection kit of ischemia modified albumin IMA and preparation method thereof | |
| Laux | Development of biological standards for the quality assurance of presumptive testing reagents | |
| CN102095696A (en) | Homocysteine measuring method and reagent | |
| CN102866197B (en) | Method for quickly detecting concentrations of various electrolytes by ion-selective electrodes | |
| CN107153044A (en) | The homocysteine kit and its detection method of a kind of modified form | |
| CN105842437A (en) | Kit for detecting D-3-hydroxybutyric acid and preparation method of kit | |
| JPS60184385A (en) | Stabilized enzyme conjugate composition | |
| CN102747133B (en) | Adenosine deaminase (ADA) detection reagent kit and preparation method thereof | |
| CN101221129B (en) | Sulfated bile acid enzyme fluorescence capillary analytical method and enzyme fluorescence quantitative reagent kit | |
| CN103163291A (en) | Kit and operation method thereof | |
| CN106680222B (en) | Cholinesterase measures reagent and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |